Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
I’ll go so far as to say that probiotics for myeloma patients and survivors is/are as important as any chemotherapy regimen. I say this because newly diagnosed myeloma (NDMM) patients these days can reasonably expect to live for 8-10 years depending on your age, stage, symptoms, risk, etc. etc.
Unfortunately, conventional oncology will focus on chemo, radiation and surgery to manage your MM. However, your body, immune function, gastrointestinal system, all will have to deal with wave after wave of toxicity.
Further, conventional oncology and the FDA do not learn about or understand the benefit of a therapy such as probiotics for myeloma.
I understand how and why conventional, FDA approved SOC therapy works for a rare blood cancer such as MM. But NDMM patients may not.
I often lament that “I wish I knew then what I know now.”
Just because your oncologist does not prescribe supplements such as curcumin, resveratrol, omega-3 fatty acids and probiotics for myeloma does not mean that these nutritional supplement will not add quality and quantify of life.
If you would like to learn more about evidence-based but non-conventional therapies to manage you and your MM email me at David.PeopleBeatingCancer@gmail.com
To explore the beneficial role of SCFAs, we performed in vitro assays in MM cell lines. Acetate, butyrate, and propionate efficiently inhibited cell growth in the millimolar range both in JJN3-GFP (IC50 acetate: 7.81 mmol/L, IC50 butyrate: 1.50 mmol/L, IC50 propionate: 5.10 mmol/L) and in U266-GFP (IC50 acetate: 22.52 mmol/L, IC50 butyrate: 1.28 mmol/L, IC50 propionate: 6.28 mmol/L) cell lines (Fig. 6C).
These results indicate that some gut microbiota metabolites have antiproliferative effects on myeloma cell lines. Additionally, we tested the combination of butyrate or propionate with the first-line treatment bortezomib, revealing synergic effects in both cases (Fig. 6D)…
In summary, the present study strongly supports that SCFA production is associated with delayed MGUS progression to MM and a better response to therapy.
Importantly, the study of the SCFA pathways and levels revealed that butyrate and propionate were associated with the progression and a better response. Due to the low number of patients in one of the branches, we have not been able to observe significant differences. However, the metabolism of propionate could potentially have an influence on overall survival.
Further studies with a larger cohort are needed to validate this finding. The in vitro analysis in MM lines after treatment with these metabolites revealed an antiproliferative potential of these metabolites in cell lines and the combination of butyrate or propionate with bortezomib had a synergic effect which could be explored as a therapeutic option.
These observations, corroborated by two independent cohorts, are in line with previous suggestions of a protective role of these compounds, particularly butyrate (19), based on three independent studies by Jian and colleagues (15), Pianko and colleagues (22), and Shah and colleagues (23).
In the first study, Clostridium butyricum, a butyrate producer, was decreased in abundance in patients with MM.
In the second and third studies, the butyrate producer Eubacterium hallii and butyrate levels were increased in MRD-negative patients with MM. Although further validation will be necessary, our data also point to the value of SCFA producers such as Agathobacter, as possible biomarkers of disease progression and response to treatment.
In addition to the low diversity associated with poor responders, our results underscore the importance of the gut microbiota for MM evolution and its response to treatment.”